Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes

Diabetologia

Volumn 58, Issue 12, 2015, Pages 2688-2698

  ten Kulve, Jennifer S ^a   Veltman, Dick J ^a   van Bloemendaal, Liselotte ^a   Barkhof, Frederik ^a   Deacon, Carolyn F ^b   Holst, Jens J ^b   Konrad, Robert J ^c   Sloan, John H ^c   Drent, Madeleine L ^a,d   Diamant, Michaela ^a   IJzerman, Richard G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ELI LILLY AND COMPANY   (United States)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

fMRI; Food intake; GLP 1; Neuroimaging; Obesity; Type 2 diabetes

Indexed keywords

EXENDIN 9 39; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HORMONE; HORMONE RECEPTOR BLOCKING AGENT; PLACEBO; SULFONYLUREA; UNCLASSIFIED DRUG; EXENDIN (9-39); GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; OXYGEN; PEPTIDE FRAGMENT;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; AUDIOVISUAL EQUIPMENT; BODY MASS; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG WITHDRAWAL; ECHO PLANAR IMAGING; FEEDING; FEMALE; FOOD INTAKE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; INFUSION PUMP; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SCANNER; NUTRITIONAL STATUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REWARD; SATIETY; AGED; AGONISTS; BLOOD; FOOD; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOSTIMULATION; POSTPRANDIAL STATE; PSYCHOLOGY; PSYCHOPHYSIOLOGY;

ADULT; AGED; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOOD; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBESITY; OXYGEN; PEPTIDE FRAGMENTS; PHOTIC STIMULATION; POSTPRANDIAL PERIOD; REWARD; SATIETY RESPONSE;

EID: 84946499280     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3754-x     Document Type: Article

References (50)

1. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW (2006) Central nervous system control of food intake and body weight. Nature 443:289–295
2. Chaudhri OB, Wynne K, Bloom SR (2008) Can gut hormones control appetite and prevent obesity? Diabetes Care 31(Suppl 2):S284–S289
3. Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300–1304
4. Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515–520
5. de Rodriquez FF, Navarro M, Alvarez E et al (2000) Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49:709–717
6. Szayna M, Doyle ME, Betkey JA et al (2000) Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936–1941
7. Verdich C, Flint A, Gutzwiller JP et al (2001) A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382–4389
8. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344:d7771
9. Shugrue PJ, Lane M, Merchenthaler I (1996) Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137:5159–5162
10. Turton MD, O'Shea D, Gunn I et al (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69–72
11. Meeran K, O'Shea D, Edwards CM et al (1999) Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140:244–250
12. Merchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261–280
13. Williams DL, Baskin DG, Schwartz MW (2009) Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150:1680–1687
14. Secher A, Jelsing J, Baquero AF et al (2014) The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124:4473–4488
15. Bloemendaal Lv, Ten Kulve JS, la Fleur SE, IJzerman RG, Diamant M (2014) Effects of GLP-1 on appetite and body weight: focus on the central nervous system. J Endocrinol 221:1–16
16. Patterson JT, Ottaway N, Gelfanov VM et al (2011) A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. ACS Chem Biol 6:135–145
17. Steinert RE, Schirra J, Meyer-Gerspach AC et al (2014) Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men. Am J Clin Nutr 100:514–523
18. Barrera JG, Jones KR, Herman JP, D'Alessio DA, Woods SC, Seeley RJ (2011) Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci 31:3904–3913
19. van Bloemendaal L, IJzerman RG, Ten Kulve JS et al (2014) GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 63:4186–4196
20. Rothemund Y, Preuschhof C, Bohner G et al (2007) Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals. Neuroimage 37:410–421
21. Stoeckel LE, Weller RE, Cook EW III, Twieg DB, Knowlton RC, Cox JE (2008) Widespread reward-system activation in obese women in response to pictures of high-calorie foods. Neuroimage 41:636–647
22. LaBar KS, Gitelman DR, Parrish TB, Kim YH, Nobre AC, Mesulam MM (2001) Hunger selectively modulates corticolimbic activation to food stimuli in humans. Behav Neurosci 115:493–500
23. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535–539
24. Sloan JH, Siegel RW, Ivanova-Cox YT, Watson DE, Deeg MA, Konrad RJ (2012) A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon. Clin Biochem 45:1640–1644
25. Green BD, Irwin N, Gault VA, Bailey CJ, O'Harte FP, Flatt PR (2005) Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice. J Endocrinol 185:307–317
26. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR (1995) Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95:417–421
27. Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M (1998) Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 101:1421–1430
28. Melhorn SJ, Tyagi V, Smeraglio A, Roth CL, Schur EA (2014) Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans. Appetite 82C:85–90
29. Pannacciulli N, Le DS, Salbe AD et al (2007) Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. Neuroimage 35:511–517
30. Small DM, Zatorre RJ, Dagher A, Evans AC, Jones-Gotman M (2001) Changes in brain activity related to eating chocolate: from pleasure to aversion. Brain 124:1720–1733
31. Pelchat ML, Johnson A, Chan R, Valdez J, Ragland JD (2004) Images of desire: food-craving activation during fMRI. Neuroimage 23:1486–1493
32. Hare TA, O'Doherty J, Camerer CF, Schultz W, Rangel A (2008) Dissociating the role of the orbitofrontal cortex and the striatum in the computation of goal values and prediction errors. J Neurosci 28:5623–5630
33. Alhadeff AL, Rupprecht LE, Hayes MR (2012) GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 153:647–658
34. Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP (2012) The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci 32:4812–4820
35. Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224
36. Plamboeck A, Veedfald S, Deacon CF et al (2013) The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol
37. Inokuchi A, Oomura Y, Nishimura H (1984) Effect of intracerebroventricularly infused glucagon on feeding behavior. Physiol Behav 33:397–400
38. Page KA, Seo D, Belfort-DeAguiar R et al (2011) Circulating glucose levels modulate neural control of desire for high-calorie foods in humans. J Clin Invest 121:4161–4169
39. DeSilva A, Salem V, Long CJ et al (2011) The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 14:700–706
40. Gutzwiller JP, Drewe J, Goke B et al (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541–R1544
41. Naslund E, Barkeling B, King N et al (1999) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23:304–311
42. Astrup A, Rossner S, Van GL et al (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374:1606–1616
43. Rosenstock J, Klaff LJ, Schwartz S et al (2010) Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 33:1173–1175
44. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781–792
45. Tomasi D, Wang GJ, Wang R et al (2009) Association of body mass and brain activation during gastric distention: implications for obesity. PLoSOne 4:e6847
46. Nauck MA, Niedereichholz U, Ettler R et al (1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981–E988
47. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM (1998) Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68:525–530
48. Deane AM, Nguyen NQ, Stevens JE et al (2010) Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 95:215–221
49. Salehi M, Vahl TP, D'Alessio DA (2008) Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab 93:4909–4916
50. Nicolaus M, Brodl J, Linke R, Woerle HJ, Goke B, Schirra J (2011) Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab 96:229–236